Search

Displaying results 7161 - 7170 of 8169 in total
  1. Drug

    5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole

    go.drugbank.com/drugs/DB08722
    Experimental

    These are aromatic compounds containing an ether group substituted with a benzene ring. 5-(7-(6-chloro-4-(5-hydro-4-methyl-2-oxazolyl)phenoxy)heptyl)-3-methyl isoxazole targets the protein genome polyprotein

  2. Drug

    Deanol

    go.drugbank.com/drugs/DB13352
    Investigational

    It has been also used as an ingredient in skin care, and in cognitive function- and mood-enhancing products.

  3. Drug

    Nogapendekin alfa

    go.drugbank.com/drugs/DB18740
    ApprovedInvestigational

    Nogapendekin alfa is a human IL-15N72D variant. It is one of the active ingredients in Anktiva, a combination product also containing inbakicept, where a single inbakicept is complexed with two nogapendekin alfa components. This combinat...

    Synonyms: Human interleukin 15 (72-aspartic acid) (human il-15 n72>d isoform), Il-15n72d:il-15rec-su/fc soluble complex i
  4. Drug

    RI 624

    go.drugbank.com/drugs/DB05892
    Experimental

    RI 624 is a novel humanized monoclonal antibody that blocks nerve growth factor (NGF), a key mediator of acute and chronic pain. RI 624 is being developed by Rinat and is currently in Phase I clinical trials.

  5. Drug

    Picolinic acid

    go.drugbank.com/drugs/DB05483
    Experimental

    It acts as an anti-infective and immunomodulator and is produced in approximately 25-50 mg quantities by the body on a daily basis through the breakdown of tryptophan. … Picolinic acid has been shown to be an anti-viral in vitro and in vivo, and sometimes works in conjunction with other cytokines such as interferon gamma to affect immune responses.

  6. Drug

    CX516

    go.drugbank.com/drugs/DB06247
    Investigational

  7. Drug

    CMLVAX100

    go.drugbank.com/drugs/DB05164
    Experimental

    CMLVAX100 is a vaccine targeting the BCR-ABL-derived p210 fusion protein which reduces residual disease in some patients with chronic myeloid leukemia. It is developed by Breakthrough Therapeutics and has completed phase I of its clinica...

  8. Drug

    G4460

    go.drugbank.com/drugs/DB06359
    Investigational

  9. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10596
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen

  10. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB10597
    ApprovedWithdrawn

    Vaccines provide protection from influenza by exposing the immune system to the virus (or parts of the virus) which stimulates an immunological defence against future exposure to the virus, or "antigen